Controlling heart rate with Ivabradine in sepsis patients

Effect of Heart Rate Control With Ivabradine on Hemodynamic in Patients With Sepsis: a Prospective, Multicenter, Randomized Controlled Trial

This study is testing if adding Ivabradine to standard treatment can help lower heart rates in sepsis patients who have a fast heartbeat and see if it improves their overall health and survival.

Quick facts

• Phase: Phase 4
• Study type: Interventional
• Enrollment: 172 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Second Affiliated Hospital of Guangzhou Medical University (Academic / other)
• Locations: 3 sites (Guangzhou, Guangdong and 2 other locations)
• Trial ID: NCT05882708 on ClinicalTrials.gov

What this trial studies

This study investigates the effects of Ivabradine on heart rate and hemodynamics in patients diagnosed with sepsis who exhibit tachycardia despite standard treatment. A total of 172 adult patients will be enrolled and randomly assigned to receive either standard treatment or standard treatment plus Ivabradine within the first 96 hours of diagnosis. The primary focus is to achieve a target heart rate of 70 to 94 bpm and assess the impact on various clinical outcomes, including mortality and organ support needs, over a follow-up period of 28 days. The study aims to determine the safety and efficacy of Ivabradine in this critical patient population.

Who should consider this trial

Good fit: Ideal candidates are adult patients aged 18 and older diagnosed with sepsis and exhibiting tachycardia despite adequate treatment.

Not a fit: Patients who have previously received Ivabradine therapy or have an allergy to it will not benefit from this study.

Why it matters

Potential benefit: If successful, this approach could improve survival rates and overall outcomes for patients with sepsis by effectively managing heart rate.

How similar studies have performed: While recent studies on this topic are limited, this investigation aims to explore a novel approach to heart rate control in sepsis patients.

Eligibility criteria

Inclusion Criteria:

1. Adult patients aged 18 years or above.
2. Being treated in an intensive care unit.
3. Sepsis is diagnosed according to Sepsis-3.0 criteria, which is defined as patients requiring antimicrobial agents due to confirmed or suspected infection, acute increase in the SOFA score at least 2 points.
4. Mean arterial pressure (MAP) is maintained ≥65 mmHg with adequate volume resuscitation and vasopressor therapy. Volume resuscitation is considered adequate when Central Venous Pressure (CVP) \> 8mmHg, global end-diastolic volume index (GEDI) \> 680ml/m2 and resting inferior vena cava (IVC) diameter \> 1.5cm.
5. Patients are in a relatively stable period of hemodynamics, as defined that the targe mean arterial pressure are maintained with the same dosage of vasopressors for at least 2 h.
6. Sinus rhythm with heart rate ≥ 95bpm maintain for at least 2 hours but less than 72 hours.

Exclusion Criteria:

1. Patients who had received ivabradine therapy or known allergy to it prior to randomization.
2. Patients with severe liver dysfunction (Child-C grade).
3. Patients with a history of pre-existing chronic renal failure (glomerular filtration rate less than 15 ml/min/1.73 m2), except patients treated with continuous renal replacement therapy (CRRT).
4. Patients with known seizure disorder.
5. Patients with any contraindication to gastrointestinal drug administration.
6. Pregnant or lactating patients.
7. patients requiring the use of potent cytochrome CYP3A4 inhibitors such as antifungals of the azole-type (specifically ketoconazole and itraconazole), macrolide antibiotics (specifically clarithromycin and erythromycin) and HIV protease inhibitors (specifically nelfinavir and ritonavir).
8. Patients with active bleeding;
9. Patients with cardiac dysfunction caused by non-septic causes such as recent (\< 2months) acute myocardial infarction, chronic cardiac dysfunction (NYHA Class Ⅳ), congenital heart disease, pericardial tamponade, severe aortic regurgitation and aortic coarctation before enrollment.
10. Patients with sinoatrial block, sick sinus syndrome, atrioventricular block or heart rate dependence on pacemaker.
11. Patients with refractory shock, which may be considered if one of the following conditions still exists in spite of active volume resuscitation, high doses of vasoactive drugs (VIS score \>120), and other regular therapy: 1) Worsening hypotension (MAP\<65mmHg); 2) Lactate persistence\>5mmol/L (two times in a row with an interval of more than 30min), and a progressive upward trend; 3) Mixed venous blood oxygen saturation (SvO2) sustained \<55% (more than two consecutive times, more than 30min apart), and progressive deterioration. The above conditions lasted for more than 5 hours.
12. Use of beta blockers within 24 hours before enrollment.
13. Pheochromocytoma patients.
14. After cardiopulmonary resuscitation.
15. Patients who have been enrolled in another interventional clinical study.

Where this trial is running

Guangzhou, Guangdong and 2 other locations

• the Affiliated Panyu central Hospital of Guangzhou Medical University — Guangzhou, Guangdong, China (Recruiting)
• the Second Affiliated Hospital of Guangzhou Medical University — Guangzhou, Guangdong, China (Recruiting)
• the Third Affiliated Hospital of Guangzhou Medical University — Guangzhou, Guangdong, China (Recruiting)

Study contacts

• Study coordinator: Zhenhui Zhang, PhD

Conditions Sepsis; Ivabradine; Hemodynamics; Heart Rate Control